Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types. It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products. However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
Gene therapy is expected to be one of the next big paradigm shift in pharmacology due to the extensive on-going research studies, both at academic and industry level. Gene therapy is one of the most exciting approaches for the treatment of ovarian cancer. Replacement gene therapy is gaining attention as it has the potential to cure ovarian cancer and can be used as a promising option for long-lasting treatment.
In 2018, the global Gene Therapy for Ovarian Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Gene Therapy for Ovarian Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for Ovarian Cancer development in United States, Europe and China.
The key players covered in this study
Market segment by Type, the product can be split into
Market segment by Application, split into
Ovarian Cancer (unspecified)
Recurrent Ovarian Epithelial Cancer
Platinum-Resistant Ovarian Cancer
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Gene Therapy for Ovarian Cancer status, future forecast, growth opportunity, key market and key players.
To present the Gene Therapy for Ovarian Cancer development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Gene Therapy for Ovarian Cancer are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.